AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03012373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ear acupressure alone
Description: The magnet pellets were placed with adhesive tape at shenmen point of both ears and were pressed 5 times every 5 minutes for 15 minutes then were attached until next treatment and change now one. The patients received this treatment 2 times a week for 4 weeks.
Study NCT03012373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus ear acupressure
Description: Acupuncture included Hegu (LI 4) and Zusanli (ST 36) on both hands and legs with electrical stimulation was conducted. The frequency of electrical stimulation was 5 Hz and wave form was adjustable. The intensities of the stimulation were increased in 1 mA increments to maximal tolerable intensity. At the same time, The magnet pellets were placed with adhesive tape at shenmen point of both ears and were pressed 5 times every 5 minutes for 15 minutes. After 15 minutes treatment, acupuncture needles were removed and magnet pellets were attached until next treatment and change now one. The patients received this treatment 2 times a week for 4 weeks.
Study NCT03294551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine Reminder Recall - Autodialer
Description: Investigators will send out HPV vaccine reminder recall notices via autodialer message to the parents of adolescents 11-14 years of age who are eligible to receive a dose of the HPV vaccine per the records in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of the various modalities or reminders as compared to the standard of care control (no reminders)
Study NCT03294551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine Reminder Recall - Texting
Description: Investigators will send out HPV vaccine reminder recall notices via text message to the parents of adolescents 11-14 years of age who are eligible to receive a dose of the HPV vaccine per the records in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of the various modalities or reminders as compared to the standard of care control (no reminders)
Study NCT00576238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betamethasone valerate
Description: Topical application according to a fixed schedule for three weeks
Study NCT00576238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasone valerate
Description: Topical application according to a fixed schedule for three weeks
Study NCT01116778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eN-Lac®
Description: One capsule with 2x10\^9 colony forming unit (cfu) LP GMNL-32, once daily, po
Study NCT01116778 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: One placebo capsule, once daily, po
Study NCT00907179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH 589
Description: LBH589 three-times-a-week (doses will be at least 2 days apart, e.g. Monday, Wednesday, Friday), until disease progression or intolerable toxicities LBH589 will start the week prior to the first pemetrexed cycle and PD studies will be performed (week -1).~Dose level: 1 LBH589: 10 mg Pemetrexed: 500 mg/m2~Dose level: 2 LBH589: 15 mg Pemetrexed: 500 mg/m2~Dose level: 3 LBH589: 20 mg Pemetrexed: 500 mg/m2~Dose level: 4 LBH589: 30 mg Pemetrexed: 500 mg/m2
Study NCT00907179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given.
Study NCT03207373 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stress test (ECG)
Description: Every study participant undergoes a standard diagnostic stress ECG
Study NCT00576238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: urea
Description: Topical application twice daily for up to 6 months
Study NCT02269722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular compression device- RADAR TM-Short clamp time
Description: A clamp is placed on the radial artery following cardiac catheterization for 20 minutes
Study NCT02269722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular compression device RADAR TM-Long clamp time
Description: A clamp is placed on the radial artery following cardiac catheterization for 20 minutes
Study NCT00546364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2
Description: Ixabepilone, 40 mg/m\^2, administered as a 3-hour intravenous (IV) infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
Study NCT00546364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2
Description: Ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
Study NCT00546364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2
Description: Docetaxel 75 mg/m\^2 administered as a 1-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
Study NCT02043925 — intervention group
Intervention type: DRUG
Intervention: drugs linked with QT-prolongation
Description: all the drugs that are mentioned in the lists of QT-prolonging drugs of CredibleMeds (www.crediblemeds.org)
Study NCT03655834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: patients will be administered a microdose with subsequent pharmacokinetic assessment.
Study NCT01420510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adelmidrol vaginal gel
Description: Application of a Adelmidrol vaginal gel
Study NCT01420510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal gel
Description: Application of a placebo vaginal gel
Study NCT04489979 — intervention group
Intervention type: OTHER
Intervention: Antibiotics
Description: Children with epididymitis / orchitis who were treated by antibiotics in addition to analgetics.
Study NCT02058732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Subjects will have an MRI that lasts approximately 60 minutes at the same time points as during the stem cell study schedule; once before the stem cell surgery, and again at 1, 6, 12, 18, 24, 36, and 48 months after receiving stem cells. This magnetic resonance imaging(MRI)scan will be of the cervical spine and brain.
Study NCT02109159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A short online video with emotional content
Study NCT02109159 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A short online video with less emotional content
Study NCT00249574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: Human subjects HIV, HCV
Study NCT00249574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegInterferon
Description: intervention drug 1. buprenorphine/naloxone. street-recruited heroin users induced on bup/naloxone for period of 3-6 months, after which the second intervention is offered. intervention drug 2: pegInterferon/ribavirin. subjects interested in initiation treatment for HCV are offered pegInterferon, 180ug SQ/wk and ribavirin, 800-1200 mg daily for the standard duration of HCV treatment as dictated by genotype.
Study NCT04041336 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Description: Non-invasive method of acquiring cross sectional imaging of tissues using the coherent property of light
Study NCT04051957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate
Description: The starting dose will be Isosorbide Mononitrate 60 mg ER daily and after 4 weeks, if tolerated but response is not achieved, the dose will be escalated to Isosorbide Mononitrate 120 mg ER daily (2 tabs of 60 mg ER tablets).
Study NCT04051957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo will be given daily and will be doubled after 4 weeks of start of therapy.
Study NCT03381456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LICI
Description: Paired pulse TMS to measure LICI and late cortical disinhibition
Study NCT02753010 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric emptying of carbohydrate-rich beverage
Description: Old women with acute hip fracture with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied for retention in the elderly with acute trauma.
Study NCT02753010 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric emptying of carbohydrate-rich beverage
Description: Old women on waiting list for hip joint replacement with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied as comparator in the elderly without acute trauma..
Study NCT02753010 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric emptying of carbohydrate-rich beverage
Description: Young healthy women with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied as comparator in young women.
Study NCT02307916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF-2
Description: The FGF-2 method of use comprises a pledget of gelatin foam with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of Tisseel, a fibrin glue used for applications in ear surgery.
Study NCT02307916 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator using a sterile saline solution.
Study NCT02495922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elotuzumab
Description: 10 mg/kg in the vein( i.v) on day 1,8 and 15 in induction cycle 1 and 2, on day 1 and 11 in induction cycle 3 and 4 (Arm B1 and B2). 10 mg/kg i.v. on day 1,8 and 15 in consolidation cycle 1 and 2 (Arm A2 and B2), 10 mg/kg i.v. on day 1 and15 in maintenance cycle 1-6, 10 mg/kg i.v. on day 1 in maintenance cycle 7-26 (Arm A2 and B2)
Study NCT02495922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: 25 mg per os on day 1-14 in induction cycle 1-4, 25 mg p.o. on day 1-14 in consolidation cycle 1 and 2, 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-26 (all arms)
Study NCT02495922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg per os on day 1-14 in induction cycle 1-4, 25 mg p.o. on day 1-14 in consolidation cycle 1 and 2, 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-26 (all arms)
Study NCT02495922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: all arms: 1,3 mg/m\^2 subcutaneous on day 1, 4, 8 and 11 in 4 induction cycles, 1,3 mg/m\^2 subcutaneous on day 1, 8 and 15 in 2 cycles of consolidation
Study NCT02495922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: all arms: 1,3 mg/m\^2 subcutaneous on day 1, 4, 8 and 11 in 4 induction cycles, 1,3 mg/m\^2 subcutaneous on day 1, 8 and 15 in 2 cycles of consolidation
Study NCT02495922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 in induction cycles 1 and 2. 20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 in induction cycles 3 and 4 (Arms A1 and A2).~8 mg per os and 12 mg i.v. on day 1, 8 and 15 and 20 mg per os on days 2,4,5, 9, 11 and 12 in induction cycles 1 and 2. 8 mg per os and 12 mg i.v. on day 1, and 11, 20 mg per os on days 2,4,5,8, 9, and 12 in induction cycles 3 and 4 (Arms B1 and B2).~20 mg per os on days 1,2, 8,9, 15 and 16 in both cycles of consolidation (Arms A1 and B1). 8 mg per os and 12 mg i.v. on days 1, 8 and 15 and 20 mg per os on days 2, 9 and 16 in both consolidation cycles (Arms A2 and B2).~12 mg per os on day 1 and 15 in maintenance cycles 1-6, 12 mg per os on day 1 of maintenance cycles 7 and following (Arms A1 and B1). 4 mg per os and 8 mg i.v. on day 1 and 15 in maintenance cycles 1-6, 4 mg per os and 8 mg i.v. on day 1 of maintenance cycles 7 and following (Arms A2 and B2).
Study NCT02495922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 in induction cycles 1 and 2. 20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 in induction cycles 3 and 4 (Arms A1 and A2).~8 mg per os and 12 mg i.v. on day 1, 8 and 15 and 20 mg per os on days 2,4,5, 9, 11 and 12 in induction cycles 1 and 2. 8 mg per os and 12 mg i.v. on day 1, and 11, 20 mg per os on days 2,4,5,8, 9, and 12 in induction cycles 3 and 4 (Arms B1 and B2).~20 mg per os on days 1,2, 8,9, 15 and 16 in both cycles of consolidation (Arms A1 and B1). 8 mg per os and 12 mg i.v. on days 1, 8 and 15 and 20 mg per os on days 2, 9 and 16 in both consolidation cycles (Arms A2 and B2).~12 mg per os on day 1 and 15 in maintenance cycles 1-6, 12 mg per os on day 1 of maintenance cycles 7 and following (Arms A1 and B1). 4 mg per os and 8 mg i.v. on day 1 and 15 in maintenance cycles 1-6, 4 mg per os and 8 mg i.v. on day 1 of maintenance cycles 7 and following (Arms A2 and B2).
Study NCT01081756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-hCG
Description: r-hCG (250 mcg) injection subcutaneously (s.c.) or intramuscularly (i.m.)
Study NCT01081756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urinary-hCG
Description: Urinary hCG (10,000 IU) injection s.c. or i.m.
Study NCT03817203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape application
Description: Kinesio tape application combined with pelvic floor exercises will be performed.Taping is carried out for 2 days/week in 6 weeks. The exercise program is performed every day for 6 weeks
Study NCT03817203 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tape application
Description: Sham tape application combined with pelvic floor exercises will be performed.Sham taping is carried out for 2 days/week in 6 weeks. The exercise program is performed every day for 6 weeks
Study NCT03261323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast-Q questionnaire
Description: Developed out of Memorial Sloan-Kettering Institute for Cancer Research, this questionnaire is designed to create a patient-reported outcome measure to provide quantifiable information about the impact and effectiveness of breast surgery. In this study it will be used for quality of life assessment
Study NCT03261323 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breast-Q questionnaire
Description: Developed out of Memorial Sloan-Kettering Institute for Cancer Research, this questionnaire is designed to create a patient-reported outcome measure to provide quantifiable information about the impact and effectiveness of breast surgery. In this study it will be used for quality of life assessment
Study NCT01977885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Protein Diet
Description: All participants will be individually counseled by an RD for \~ 4 sessions (30 to 60 minutes)to meet weight loss goals. During the duration of the study, participants will be required to attend a 30 to 60 minute group educational/motivational meeting weekly (first 1 to 2 months) and then biweekly (for the remainder of the study). Diet recommendations will include high quality proteins with an emphasis on lean meats with protein being targeted for every meal and snack. Regarding beef intake specifically, the prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or \~100 grams. This amount of lean cooked beef provides an average of \~25-30 grams of protein per day (www.beefnutrition.org/leanbeef.aspx). This combined with reducing energy from carbohydrates and fat from other sources will create an overall energy deficit of 500 kcal/day. This diet will also include 5 servings/day of vegetables and 2-3 servings/day of fruit
Study NCT01977885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will be prescribed a supervised exercise program with required attendance of 3 nonconsecutive days per week (75 minutes each session). A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. With specific regard to strength training, 50% of the resistance work will involve primary muscle groups of the lower body with the main focus being the gluteal and quadriceps groups (squats, lunges, etc.). The remaining 50% of work will dedicate 25% to the core stabilizers with the final 25% being the upper body. Transitions between segments of training will be used for recovery and social support enhancement. Note that all aspects of the exercise intervention will be progressive in intensity (i.e., starting at lower end of intensity or \~50% of maximal capacity), and duration (i.e., from 15 minutes to 35 minutes of exercise and adding a few minutes each session).
Study NCT02186184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology
Study NCT02186184 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthokeratology
Study NCT02186184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacle
Study NCT02186184 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacle
Study NCT03064672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcervical Balloon Catheters
Description: induction of labor by transcervical Balloon Catheters insertion
Study NCT02813122 — intervention group
Intervention type: DEVICE
Intervention: x-ray
Description: x-ray for the detection of leaks and bleeding
Study NCT01307033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0954A
Description: Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
Study NCT01307033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-954H
Description: Tablet containing losartan potassium (50 mg) and hydrochlorothiazide (12.5 mg), once daily
Study NCT01307033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to MK-0954A
Description: Placebo tablet to match MK-0954A, once daily
Study NCT01307033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-954H
Description: Placebo tablet to match MK-954H, once daily
Study NCT00570648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium hyaluronate
Description: 1% sodium hyaluronate applied at the end of corneal transplant surgery. The amount will be determined on how much is necessary to cover the ocular surface.
Study NCT00555087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate and/or PDE-5
Description: Testosterone Undecanoate 1000 mg IM injection; PDF5 tab, 20 mg
Study NCT02553694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced education
Description: Investigator created video to help educate subject before the in-laboratory split night polysomnogram. The subject will watch the short video immediately prior to the initiation of the in-laboratory polysomnogram.
Study NCT02553694 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual education
Description: Usual education by American Academy of Sleep Medicine (AASM)- created educational pamphlets
Study NCT02553694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual education
Description: Usual education by American Academy of Sleep Medicine (AASM)- created educational pamphlets
Study NCT02553694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual follow up
Description: MD will follow up by phone after the in-laboratory split night polysomnogram
Study NCT02553694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced follow up
Description: Sleep center non-MD staff member will follow up by phone after the in-laboratory split night polysomnogram
Study NCT02553694 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced follow up
Description: Sleep center non-MD staff member will follow up by phone after the in-laboratory split night polysomnogram
Study NCT01934140 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: 1 dose administered intramuscularly in the non-dominant deltoid region.
Study NCT01934140 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal vaccine GSK134612
Description: 1 dose administered intramuscularly in the non-dominant deltoid region.
Study NCT03658226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychodynamic Interpersonal Therapy (PIT)
Description: PIT is conversational model of psychotherapy; participants will receive 8 sessions of this therapy once weekly. The first session will be 2 hours and all remaining sessions will be 50 minutes.
Study NCT01831128 — intervention group
Intervention type: DEVICE
Intervention: ASV Treatment
Study NCT01098890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Plasminogen Activator
Description: 2mg tPA will be given every twelve hours for a maximum of 5 doses
Study NCT01098890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered every 12 hours for a maximum of 5 doses.
Study NCT00947531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Study NCT00947531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline Solution